Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Prices Public Offering, Moves to Nasdaq

NEW YORK (GenomeWeb News) – Cancer Genetics today announced the public offering of 1.5 million shares of its common stock at $10 per share and the migration of its stock to the Nasdaq Capital Market.

Its stock had been trading on the OTC QB since the company went public in April.

The Rutherford, NJ-based cancer diagnostics firm said that net proceeds will be used to expand its sales and marketing operations; further commercialize products; invest in its joint venture with the Mayo Clinic called OncoSpire; retire mezzanine financing; continue R&D; and fund other general working capital needs

Aegis Capital is the sole book-running manager for the offering, and Feltl and Co., is the co-lead manager.

Cancer Genetics has granted the underwriters a 45-day option to purchase up to 225,000 additional shares of its common stock to cover any overallotments. The offering is expected to close Aug. 19.

The company filed its preliminary prospectus for the offering in June.

Cancer Genetics also said that as of today its stock will trade on the Nasdaq under ticker symbol "CGIX".

Earlier this month, Cancer Genetics reported a 64 percent hike in its second quarter revenues.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.